Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
gMSC3
- Development stage
- Preclinical
- Lead developer
- Two Cells
- Modality
- Stem Cell Therapies → Cell Therapies
01
Overview
gMSC3 is an allogeneic mesenchymal stem cell (MSC) therapy being developed by Two Cells for the treatment of early osteoarthritis and fibromyalgia. The cells are produced using the company's proprietary STK® Series serum-free culture media, which is intended to maintain the cells' therapeutic potential and ensure high quality. The therapy aims to provide regenerative and immunomodulatory effects to address the underlying pathology of joint disease and chronic pain conditions. It is currently in the preclinical stage of development, representing the third generation of MSC products in the developer's pipeline.
- Other names
- allogeneic mesenchymal stem cellsgMSC (generation 3)
Beyond the preview
Go deeper on gMSC3.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on gMSC3.